Considering the evidence implicating the IL-17 axis in NAFLD and NASH, pharmacological inhibition of IL-17 signaling could be such a strategy as shown in a pre-clinical mouse model of alcohol-induced liver injury (118). Here, IL17A is linked to metabolic dysfunction-associated steatohepatitis.